Results 141 to 150 of about 11,087,757 (202)

DPP-4 Inhibitors as Antidiabetic Agents

Journal of Analytical & Bioanalytical Techniques, 2010
openaire   +1 more source

Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data. [PDF]

Diabetol Int
Miwa T, Yoshida S, Nakajima A, Koto R, Nishimura R.   +4 more
europepmc   +1 more source

DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. [PDF]

BMJ Case Rep, 2019
Padron S, Rogers E, Demory Beckler M, Kesselman M.   +3 more
europepmc   +1 more source

Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial. [PDF]

Diabetes Ther
Laffel LM.
europepmc   +1 more source

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

, 2020
Rhee SY, Lee J, Nam H, Kyoung D, Kim DJ.
europepmc   +1 more source

Jurnal kajian wanita/ Bidang Kewanitaan DPP PKS

Bidang Kewanitaan DPP PKS
core  

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013
Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-
Kishimoto M
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacoeconomic analysis of DPP-4 inhibitors

Die Pharmazie, 2013
Dipeptidyl peptidase-4 (DPP-4) inhibitors and other incretin-related drugs have attracted attention as antidiabetic agents, but they are expensive. The Japanese government has adopted a policy of reducing healthcare costs, and medical institutions must provide medical care while considering economic efficiency.
H, Teramachi, H, Ohta, T, Tachi, M, Toyoshima, T, Mizui, C, Goto, T, Tsuchiya   +6 more
openaire   +3 more sources